The Diagnosis and Clinical Management of Thrombophilia

Marcum JA McKenny JB Rosenberg RD . Acceleration of thrombin-antithrombin complex formation in rat hind quarters via heparin-like molecules bound to the endothelium. J Clin Invest 1984; 74: 341–50.

Rosenberg RD . Biochemistry of heparin antithrombin interactions, and the physiologic role of the natural anticoagulant mechanism. Am J Med 1989; 97 (suppl 3B): 2–9.

Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965; 13: 516–30.

Thaler E Lechner K. Antithrombin III deficiency and thromboembolism. Clin Haematol 1981; 10: 369–90.

Rosenberg RD . Actions and interactions of antithrombin and heparin. N Engl J Med 1975; 292: 146–51.

Vykidal R Korninger C Kyrir PA . The prevalence of antithrombin III deficiency in patients with a history of venous thromboembolism. Thromb Haemost 1985; 54: 744–5.

Tait RC Walker ID Perry DJ . Prevalence of antithrombin III deficiency subtypes in 4000 healthy blood donors. Thromb Haemost 1991; 65: 534 (Abstract).

Abildgaard U. Antithrombin and related inhibitors of coagulation. In: Poller L ed. Recent advances in blood coagulation. Edinburgh: Churchill Livingstone, 1981: 151–73.

Prochownik EV . Molecular genetics of inherited antithrombin III deficiences. Am J Med 1989; 87 (suppl 3B): 15–18.

Bock SC Wion KL Vehar GA Lawn RM . Cloning and expression of the cDNA for human antithrombin III. Nucl Acids Res 1982; 10: 8113–25.

Chandra T Stackhouse R Kidd VJ Woo SLC . Isolation and sequence characterisation of a DNA clone of human antithrombin III. Proc Natl Acad Sci USA 1983; 58: 1094.

Prochownik EV Markham AF Orkin SH . Isolation of the cDNA clone for the human antithrombin III. J Biol Chem 1983; 128: 8389–94.

Lane DA Caso R. Antithrombin III: Structure, genomic organisation, function and inherited deficiency. In: Clinical haematology: The molecular biology of coagulation, volume 2.4. London: Baillière-Tindall, 1989: 961–98.

Yue R Gertler M Starr T Koutrouby R. Alterations of plasma antithrombin III levels in ischaemic heart disease. Thromb Haemost 1976; 35: 598–606.

Meade TW Cooper J Miller GJ Howarth DJ Stirling Y. Antithrombin III and arterial disease. Lancet 1991; 338: 850–51.

Esmon CT Owen WG . Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA 1981; 78: 2249–52.

Griffin JH Evatt B Zimmerman TS Kleiss AJ Widenman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68: 1370–73.

Bertina RM Broekmans AW van der Linden IK Mertens K. Protein C deficiency in a Dutch family with thrombotic disease. Thromb Haemost 1982; 48: 1–5.

Horellou MH Conard J Bertina RM Samama M. Congenital protein C deficiency and thrombotic disease in nine French families. Br Med J 1984; 289: 1285–87.

Broekmans AW van der Linden IK Veltkamp JJ Bertina RM . Prevalence of isolated protein C deficiency in patients with venous thrombotic disease and in the population. Thromb Haemost 1983; 50: 350 (Abstract).

Gladson CL Sharrer I Hach V Beck KH Griffin J. The frequency of type I heterozygous protein C deficiency in 141 unrelated young patients with venous thrombosis. Thromb Haemost 1988; 59: 18–22.

Miletich J Sherman L Broze G Jr . Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987; 317: 991–6.

Marlar RA Montgomery RR Broekmans AW . Report on the diagnosis and treatment of homozygous protein C deficiency. Report of the Working Party on Homozygous Protein C Deficiency of the ICTH-Subcommittee on Protein C and Protein S. Thromb Haemost 1989; 61: 529–31.

Preston FE Briet E. Familial thrombophilia. In: Brenner Hoffbrand eds. Recent advances in haematology 7. London: Churchill Livingstone, 1993 (in press).

Broekmans AW . Hereditary protein C deficiency. Haemostasis 1985; 15: 233–40.

Coller BS Owen J Jesty J . Deficiency of plasma protein S, protein C, or antithrombin III and arterial thrombosis. Arteriosclerosis 1987; 7: 456–62.

Samama M Horellou MH Soria J Conard J Nicolas G. Successful progressive anticoagulation in a severe protein C deficiency and previous skin necrosis at the initiation of oral anticoagulant treatment letter. Thromb Haemost 1984; 51: 132–33.

McGehee WG Klotz TA Epstein DJ Rapaport SI . Coumarin necrosis associated with hereditary protein C deficiency. Ann Intern Med 1984; 101: 59–60.

Teepe RG Broekmans AW Vermeer BJ Nienhuis AM Loeliger EA . Recurrent coumarin-induced skin necrosis in a patient with an acquired functional protein C deficiency. Arch Dermatol 1986; 122: 1408–12.

Marlar RA Mastovich S. Hereditary protein C deficiency: A review of the genetics, clinical presentation, diagnosis and treatment. Blood Coagulat Fibrinol 1990; 1: 319–30.

Tuddenham EG Takase T Thomas AE . Homozygous protein C deficiency with delayed onset of symptoms at 7 to 10 months. Thromb Res 1989; 53: 475–84.

Tripodi A Franchi F Krachmalnicoff A Mannucci PM . Asymptomatic homozygous protein C deficiency. Acta Haematol 1990; 83: 152–55.

Bertina RM van Wijngaarden A Poot Reinalda J Poort SR Bom VJ . Determination of plasma protein S — the protein cofactor of activated protein C. Thromb Haemost 1985; 53: 268–72.

Dahlback B. Inhibition of protein C cofactor function of human and bovine protein S by C4b-binding protein. J Biol Chem 1986; 261: 12022–27.

Comp PC Forristall J West CD Trapp RG . Free protein S levels are elevated in familial C4b-binding protein deficiency. Blood 1990; 76: 2527–29.

Griffin JH Fernandez JA Gruber A. Critical reevaluation of free protein S (PS) and C4b-binding protein (C4BP) levels and implications for thrombotic risk. Thromb Haemost 1991; 65: 711 (Abstract).

Comp PC Doray D Patton D Esmon CT . An abnormal plasma distribution of protein S occurs in functional protein S deficiency. Blood 1986; 67: 504–508.

Pabinger I Bertina RM Lechner A . Protein S deficiency in seven Austrian families. Thromb Res 1986; 42 (suppl VI): 269.

Engesser L Kluft C Briet E Brommer EJ . Familial elevation of plasma histidine-rich glycoprotein in a family with thrombophilia. Br J Haematol 1987; 67: 355–58.

Sas Y Blasko Y Petro I Griffin JH . A protein S deficient family with portal vein thrombosis. Thromb Haemost 1985; 54: 724.

Goldberg SL Orthner CL Yalisove BL Elgart ML Kessler CM . Skin necrosis following prolonged administration of coumarin in a patient with inherited protein S deficiency. Am J Hematol 1991; 38: 64–66.

Grimaudo V Bachmann F Hauert J Christe M-A Kruithof EKO . Hypofibrinolysis in patients with a history of idiopathic deep vein thrombosis and/or pulmonary embolism. Thromb Haemost 1992; 67: 397–401.

Moreb J Kitchens CS . Acquired functional protein S deficiency, cerebral venous thrombosis, and coumarin skin necrosis in association with antiphospholipid syndrome: Report of two cases. Am J Med 1989; 87: 207–10.

Rodgers GM Conn MT . Homocysteine, an atherogenic stimulus, reduces Protein C activation by arterial and venous endothelial cells. Blood 1990; 75: 895–901.

Clarke R Daly L Robinson K . Hyperhomocysteinaemia and independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149–55.

Silverstein RL Nachman RL . Cancer and clotting — Trousseau's warning. N Engl J Med 1992; 327: 1163–64.

Haserick JR Lung R. Systemic lupus erythematosus preceded by false positive tests for syphilis. Ann Intern Med 1952; 37: 559–65.

Conley CL Hartmann RC . A haemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest 1952; 31: 621–23.

Machin SJ Giddings J Greaves M Hutton R . Detection of the lupus like anticoagulant: Current laboratory practice in the United Kingdom. J Clin Pathol 1990; 43: 73–79.

Taberner DA Giddings J Greaves M . The Lupus Anticoagulant Working Party of the BCSH Haemostasis and Thrombosis Task Force of the British Society for Haematology. Guidelines on testing for the lupus anticoagulant. 1991; 44: 885–89.

Harris EN Gharavi AE Patel SP Hughes GRV . Evaluation of the anticardiolipin tests: Report of an international workshop held on 4 April 1986. Clin Exp Immunol 1987; 68: 215–22.

Gastineau DA Kazmier FJ Nichols WL Bowie EJW . Lupus anticoagulant: An analysis of the clinical and laboratory features of 219 cases. Am J Hematol 1985; 19: 265–75.

Ford SE Lillicrap D Brunet D Ford P. Thrombotic endocarditis and lupus anticoagulant. Arch Pathol Lab Med 1989; 113: 350–53.

Antiphospholipid Antibodies in Stroke Study Group. Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischaemia. Stroke 1990; 21: 1268–73.

Sneddon IB . Cerebro-vascular lesions and livedo reticularis. Br J Dermatol 1965; 77: 180.

Creagh MD Greaves M. Lupus anticoagulant. Blood Rev 1991; 5: 162–67.

Triplett DA Brandt JT Musgrave KA Orr CA . The relationship between lupus anticoagulants and antibodies to phospholipid. JAMA 1988; 259: 550–54.

Branch DW Scott JR Kochenour NK Hershgold E. Obstetric complications associated with the lupus anticoagulant. N Engl J Med 1985; 313: 1322–26.

Lockshin MD Druzin ML Goei S Qamar T . Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. N Engl J Med 1985; 313: 152–56.

Creagh MD Duncan SLB McDonnell J Greaves M. The incidence of the lupus anticoagulant (LA) and anticardiolipin antibodies (ACL) in normal pregnancy. Clin Exp Rheumatol 1990; 8: 219.

Alarcon-Segovia D Sanchez-Guerrero J. Primary antiphospholipid syndrome. J Rheumatol 1989; 16: 482–87.

Malia RG Kitchen S Greaves M Preston FEP . Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990; 76: 101–107.

McNeil HP Simpson RJ Chesterman CN Krilis SA . Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β₂-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120–24.

Bevers EM Galli M Barbui T Comfurius P Zwaal RFA . Lupus anticoagulant IgG's (A) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thrombosis and Haemostasis 1991; 66: 629–32.

Antiphospholipid Antibodies in Stroke Study Group. Recurrent thromboembolic and stroke risk in patients with neurological events and antiphospholipid antibodies. Ann Neurol 1990; 28: 266.